Incidence and predictors of vancomycin-associated nephrotoxicity

Area of Science:

• Nephrology
• Infectious Diseases
• Clinical Pharmacology

Background:

• Vancomycin-associated nephrotoxicity (VAN) incidence varies, with recent studies showing over 30%.
• Predictors for VAN remain poorly defined, necessitating further investigation.
• This study focuses on a cohort with predominantly long vancomycin treatment durations.

Purpose of the Study:

• To accurately estimate the incidence of VAN in a diverse patient population.
• To identify and evaluate clinical predictors associated with VAN development.
• To analyze risk factors in patients undergoing extended vancomycin therapy.

Main Methods:

• Retrospective analysis of patients receiving vancomycin and monitored via the Outpatient Parenteral Antibiotic Therapy program.
• Nephrotoxicity defined as a ≥50% or 0.5 mg/dL increase in serum creatinine on two consecutive readings.
• Comparison of nephrotoxic vs. non-nephrotoxic groups based on vancomycin parameters, comorbidities, and concurrent treatments.

Main Results:

• Out of 579 patients, 154 (26.6%) experienced nephrotoxicity.
• Nephrotoxicity occurred within 14 days for 90 patients and after 14 days for 64 patients, with a median onset of 9 days.
• Independent predictors of nephrotoxicity included ICU admission, loop diuretic use, and cirrhosis; higher baseline creatinine showed a protective effect (P=0.0016).

Conclusions:

• VAN is a significant risk in both short and long vancomycin treatment courses.
• Key risk factors for VAN include ICU stay, concurrent loop diuretic use, cirrhosis, and initial vancomycin trough levels.
• Elevated baseline creatinine may be protective, possibly due to cautious vancomycin administration in such patients.